Profile
ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead program for TNBC will be ready for IND in H1-2025. Its platform has been validated (in-vivo and with unprecedented in-vitro characteristics) with three top 25 pharma companies in their experimental assays. ProteinQure is the only computational platform capable of designing peptides with the full complement of non-canonical amino acids, so that its peptides are 100x better than natural peptide ligands. For its own internal programs it uses the novel peptides to help deliver payloads in a tissue specific manner. Peptides are ideal for delivery of different payloads like radioisotopes and gene therapy since they are tissue specific and easier to manufacture. It also has exciting in-vivo POC for siRNA delivery to CNS.
Website
proteinqure.comContact
-
Lucas Siow, Chief Executive OfficerTel: +1 647-248-9772Email: lucas@proteinqure.com
-
-
-
-
-
Event details
Event contact
Participants
-
20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for… -
Since 2001, BioScript Solutions has supported patients with chronic illnesses and rare diseases by providing… -
Custom Biologics provides regulatory compliant potency testing and assay services for all phases of… -
Dalriada is a leading North American discovery company pioneering its novel Turn-Key™ model in small molecule… -
HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address… -
ImmunoBiochem is an innovative biopharmaceutical company developing novel bioconjugate therapeutics, such … -
Invest Ontario is a provincial agency dedicated to securing private sector strategic business and capital… -
Raising capital is a key challenge for executives at early-stage therapeutics companies. Lumerate is launching… -
mDETECT offers highly sensitive and cost-effective blood tests that can measure tumour behaviour irrespective of… -
Noa Therapeutics is a preclinical biotech company pioneering the development of homeostatic modulating small… -
Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP… -
Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating… -
ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead…
-
QReserve provides powerful enterprise-grade scheduling and resource management software to world-class… -
Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class… -
Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number… -
Stiris is a clinical trial management company conducting Phase I-IIIB trials for biotech and… -
Sussex Research Laboratories Inc. (Ottawa, Canada) is recognized as a leader in the design and synthesis of… -
SYNG Pharma is developing a new first-in-class diagnostic test and non-hormonal therapy for endometriosis. The… -
Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide… -
VeriLuce Therapeutics is an early-stage drug company developing novel small molecules targeting in dual… -
Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the… -
YYZ Pharmatech Inc. (“YYZ”) is a deep tech company endeavoring to profoundly progress…